Hisun Pharmaceuticals USA Announces U.S. Launch of Fludarabine Phosphate Injection
September 01, 2026
Bridgewater, NJ – September 1, 2026 – Hisun Pharmaceuticals USA Inc. is pleased to announce the successful U.S. launch of Fludarabine Phosphate Injection, marking another important addition to the company’s growing generic injectable portfolio in the United States.
The launch represents another milestone in Hisun Pharmaceuticals USA’s continued efforts to expand its presence in the U.S. pharmaceutical market and provide patients and healthcare providers with access to high-quality, affordable generic medicines.
Fludarabine Phosphate Injection is the latest addition to Hisun’s U.S. product portfolio and further strengthens the company’s capabilities and presence in the injectable pharmaceutical market. The successful launch reflects the close collaboration of Hisun’s global teams across manufacturing, quality, regulatory affairs, supply chain, and commercial operations.
“Bringing a new product to the U.S. market requires strong coordination across every stage, from development and regulatory approval to manufacturing and commercialization,” said a representative of Hisun Pharmaceuticals USA. “We are proud to achieve this milestone and remain committed to expanding our portfolio to better serve the needs of the U.S. healthcare market.”
Hisun Pharmaceuticals USA will continue to leverage its global manufacturing capabilities and local market expertise to introduce additional pharmaceutical products in the United States and build sustainable partnerships with customers and healthcare stakeholders.
Passion for Life, Light for Health.
About Hisun Pharmaceuticals USA
Hisun Pharmaceuticals USA Inc., based in Bridgewater, New Jersey, is the U.S. subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. The company is focused on bringing high-quality pharmaceutical products to the U.S. market and developing long-term partnerships across the healthcare industry.